Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Breast cancer (BC) represents a significant global health challenge, comprising 30% of cancer cases in women worldwide.
• The urgent need for selective and effective BC therapies drives research into innovative treatment modalities.
• Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic strategy for BC due to their unique mechanism of action.

Purpose of the Study:

• To review the current landscape of PROTACs developed for targeting breast cancer.
• To categorize existing PROTACs based on the specific types of breast cancer they target.
• To discuss the limitations and future perspectives of PROTAC technology in the context of breast cancer therapeutics.

Main Methods:

• Literature review of existing PROTAC molecules and their applications in breast cancer research.
• Analysis of PROTAC design, including target protein ligands, E3 ligase ligands, and conjugating linkers.
• Categorization of PROTACs based on breast cancer subtypes and targeted proteins.

Main Results:

• PROTACs function by hijacking the cell's natural protein degradation machinery to eliminate target proteins.
• This approach allows for the degradation of proteins previously considered undruggable, offering new therapeutic avenues.
• Current PROTAC research demonstrates potential for high efficacy at low doses due to their catalytic nature.

Conclusions:

• PROTACs represent a groundbreaking therapeutic strategy with significant potential for treating various types of breast cancer.
• Further research is needed to overcome existing limitations and fully realize the clinical utility of PROTACs in BC treatment.
• The review highlights the evolving role of PROTACs in precision oncology and their future prospects in combating breast cancer.